Nektar Therapeutics Stock Discussion

$Nektar Therapeutics(NKTR.US)$
Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024
Nektar Therapeutics (Nasdaq: NKTR) unveiled preclinical data on NKTR-0165, a TNFR2 agonist antibody aimed at treating inflammatory diseases, at the EULAR 2024 Congress. NKTR-0165 is designed to selectively stimulate TNFR2 receptor activity, which is important for inflammation control and is associ...

$Nektar Therapeutics(NKTR.US)$ why such a drop today?

$Nektar Therapeutics(NKTR.US)$ raise ur hand if u bought this above 50dollars 😂😂😂

$Nektar Therapeutics(NKTR.US)$ Nektar Therapeutics:Received Letter From Nasdaq Notifying Co It Regained Compliance With Minimum Bid Price Requirement for Continued Listing on Nasdaq

$Nektar Therapeutics(NKTR.US)$ • Nektar Therapeutics has regained full rights to its drug candidate REZPEG and is advancing Phase 2b studies for atopic dermatitis and alopecia areata.
• The company's TNFR2 agonist antibody, NKTR-0165, targets autoimmune diseases and is slated for clinical trials in the first half of 2025.
• Nektar ended the year with $329.4 million in cash and investments and expects 2024 revenues of $75...

$Nektar Therapeutics(NKTR.US)$ Nektar Therapeutics Reports Positive Preclinical Data on NKTR-255
MT Newswires· 1 min ago
Nektar Therapeutics (NKTR) said Monday that new preclinical data on NKTR-255 showed that a combination of the product candidate with obinutuzumab "significantly enhanced" the cytotoxicity of expanded Natural Killer or NK cells against rituximab-resistant Burkitt Lymphoma cells.
"Preclinical and early clinical data suggest that NKTR-255 can improve proliferation and pers...

$Nektar Therapeutics(NKTR.US)$ It needs some suberb news that can drive the stock price. It's not for short-term investment.